2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1637

Real-World Use of Tofacitinib in Rheumatoid Arthritis: Data from the Swiss Clinical Quality Management RA Registry
Abstract Number: 2523

Reasons for Provider Non-Adherence to a Treat to Target Strategy in Rheumatoid Arthritis
Abstract Number: 2335

Recent Changes of Radiological Findings and Patients’ Background of Rheumatoid Hip and Knee
Abstract Number: 1987

Recessive Coding and Regulatory Mutations in FBLIM1 Underlie the Pathogenesis of Sterile Osteomyelitis
Abstract Number: 2221

Recognition of Secondary Fibromyalgia Using an Index of 3 Components of the Multi-Dimensional Health Assessment Questionnaire: 90% Agreement with ACR Criteria for Fibromyalgia
Abstract Number: 3071

Recombinant Human Proteoglycan-4 (rhPRG4) Inhibits Monosodium Urate (MSU) Crystal Phagocytosis By Human Macrophages and Resultant Inflammatory Response
Abstract Number: 2510

Recommendations for the Use of Parenteral Methotrexate in Rheumatic Diseases
Abstract Number: 3115

Reconsidering the Juvenile Idiopathic Arthritis Core Set: How Patients and Caregivers Define Disease Activity
Abstract Number: 2148

Recruitment of Circulating Monocytes By TNF/IL-6-Induced Expression of Vascular Cell Adhesion Molecule 1 (VCAM-1) Drives Valvular Inflammation in K/B/g7 Mice
Abstract Number: 1068

Recurrence of Thrombosis Despite Negativization of Antiphospholipid Antibodies in Primary Antiphospholipid Syndrome. a Follow-up to 5 Years
Abstract Number: 2881

Reduced Hippocampal-Thalamic Fiber Tracts in Systemic Lupus Erythematosus
Abstract Number: 2452

Reduced Ovarian Reserve in Young Juvenile Idiopathic Arthritis Patients
Abstract Number: 1146

Reducing Imaging Tests for Low Back Pain: Can Patients Choose Wisely?
Abstract Number: 2542

Reducing the Dosage of Glucocorticoid to Zero Might Decrease Risk of Clinical Fractures in Patients with Rheumatoid Arthritis: Five-Year Findings of the Tomorrow Study
Abstract Number: 145

Reduction in Musculoskeletal Ultrasound (MSK-US) Payments in 2014: Effects & Consequences

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].